Intervacc AB (publ) (STO:IVACC)
Sweden · Delayed Price · Currency is SEK 1.180
-0.018 (-1.50%)
May 21, 2026, 1:13 PM CET
Intervacc AB Company Description
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care.
The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles.
The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms.
In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections.
It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Intervacc AB (publ)
| Country | Sweden |
| Founded | 1983 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Carl-Johan Dalsgaard |
Contact Details
Address: Västertorpsvägen 135 Hägersten Sweden | |
| Phone | 46 8 12 01 06 00 |
Stock Details
| Ticker Symbol | IVACC |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009607252 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl-Johan Dalsgaard M.D., Ph.D. | Chief Executive Officer |
| Jan Persson | Chief Financial Officer |
| Patrik Hellberg | Chief Investment Officer |
| Dr. Andrew Waller | Chief Scientific Officer |
| Anna-Carin Lagerlof | Sales and Marketing Director |